Janus Henderson Group PLC raised its holdings in Centene Corporation (NYSE:CNC – Free Report) by 3.8% in the first quarter, Holdings Channel.com reports. The fund owned 865,760 shares of the company’s stock after acquiring an additional 31,485 shares during the period. Janus Henderson Group PLC’s holdings in Centene were worth $28,344,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the business. DV Equities LLC bought a new stake in shares of Centene in the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. bought a new stake in Centene during the fourth quarter worth approximately $28,000. SBI Securities Co. Ltd. boosted its holdings in Centene by 118.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 749 shares of the company’s stock worth $31,000 after buying an additional 406 shares in the last quarter. Bayban acquired a new position in Centene in the fourth quarter worth approximately $33,000. Finally, MV Capital Management Inc. bought a new position in shares of Centene in the fourth quarter valued at $34,000. Institutional investors and hedge funds own 93.63% of the company’s stock.
Centene Price Performance
CNC opened at $62.23 on Monday. The firm has a market capitalization of $30.74 billion, a P/E ratio of -5.96, a PEG ratio of 0.33 and a beta of 1.08. The stock has a fifty day moving average of $63.87 and a 200-day moving average of $50.30. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 0.71. Centene Corporation has a 12-month low of $25.08 and a 12-month high of $69.36.
Analyst Ratings Changes
CNC has been the subject of several research reports. Sanford C. Bernstein raised their price objective on Centene from $48.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Centene in a report on Friday, July 17th. Wells Fargo & Company set a $69.00 price target on Centene and gave the company an “equal weight” rating in a research report on Monday, July 13th. Oppenheimer lifted their price target on Centene from $58.00 to $67.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. Finally, Robert W. Baird upped their price objective on shares of Centene from $46.00 to $66.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $67.00.
Read Our Latest Stock Analysis on CNC
Centene News Summary
Here are the key news stories impacting Centene this week:
- Positive Sentiment: Strong Q2 results and raised outlook: Centene reported adjusted earnings of $2.51 per share, well above the $1.09 consensus estimate, while revenue rose 9.9% year over year to $53.58 billion. The insurer also raised its 2026 earnings outlook to at least $4.80 per share, citing contained medical costs. Centene Lifts 2026 Outlook as Insurer Contains Medical Costs
- Positive Sentiment: Analyst support has strengthened: Zacks Research upgraded CNC from “hold” to “strong buy,” while Truist maintained its buy rating. Robert W. Baird also expects the stock to rise, providing additional support for the recent rally. Zacks.com Truist Financial Keeps Their Buy Rating on Centene
- Positive Sentiment: Momentum and valuation remain favorable: Zacks included Centene among its Rank #1 momentum stocks, and other analyses describe CNC as potentially undervalued following its earnings recovery. These reports may attract momentum and value-oriented investors. Best Momentum Stock to Buy
- Neutral Sentiment: Relative investment appeal: A comparison with UnitedHealth favors UNH because of its diversified platform, Optum growth and artificial-intelligence investments. The assessment does not identify a new negative development at Centene but could limit CNC’s appeal among managed-care investors. UnitedHealth vs. Centene
- Negative Sentiment: Medicaid and membership concerns persist: Coverage highlights declining membership and ongoing Medicaid-related pressure, which could challenge revenue growth and margins even as medical-cost trends improve. Medicaid Weighs on Centene
Centene Company Profile
Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.
Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.
Recommended Stories
- Five stocks we like better than Centene
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Corporation (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
